JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Inclusion Criteria:

• A signed written informed consent is required before performing any study-relatedoperations

• Age greater than or equal to 18 years old

• Histologically or cytologically confirmed locally advanced/metastatic, unresectablenon-squamous NSCLC with KRAS p. G12C mutation confirmed by the central lab

• No history of systemic anticancer therapy to the local advanced/metastatic disease

• Expected survival period greater than or equal to 3 months

• Having at least one target lesion according to RECIST 1.1

• Eastern Cooperative Oncology Group (ECOG) ≤ 1

Exclusion Criteria:

• Previous (≤2 years) or current solid tumors or hematologic tumors of otherpathological types

• Carry other driver gene mutations with available target therapy, or carry other KRASmutations

• Subjects with untreated central nervous system (CNS) metastases were excluded;

• Uncontrolled pleural effusion, pericardial effusion, and ascites

• Subjects with impaired heart function or clinically significant heart disease